{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:49:09Z","timestamp":1760014149421},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T00:00:00Z","timestamp":1537574400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s10147-018-1347-7","type":"journal-article","created":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T05:53:21Z","timestamp":1537595601000},"page":"222-230","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Coadministration of cytotoxic chemotherapeutic agents with irinotecan is a risk factor for irinotecan-induced cholinergic syndrome in Japanese patients with cancer"],"prefix":"10.1007","volume":"24","author":[{"given":"Ayako","family":"Tsuboya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ichi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaro","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroo","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iori","family":"Taki-Takemoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Iwai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasutsuna","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,22]]},"reference":[{"issue":"43","key":"1347_CR1","doi-asserted-by":"publisher","first-page":"12234","DOI":"10.3748\/wjg.v21.i43.12234","volume":"21","author":"K Fujita","year":"2015","unstructured":"Fujita K, Kubota Y, Ishida H et al (2015) Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. World J Gastroenterol 21(43):12234\u201312248. \n                    https:\/\/doi.org\/10.3748\/wjg.v21.i43.12234","journal-title":"World J Gastroenterol"},{"issue":"8","key":"1347_CR2","first-page":"2182","volume":"7","author":"RH Mathijssen","year":"2001","unstructured":"Mathijssen RH, van Alphen RJ, Verweij J et al (2001) Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7(8):2182\u20132194","journal-title":"Clin Cancer Res"},{"issue":"24","key":"1347_CR3","first-page":"6921","volume":"60","author":"Y Ando","year":"2000","unstructured":"Ando Y, Saka H, Ando M et al (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60(24):6921\u20136926","journal-title":"Cancer Res"},{"issue":"8","key":"1347_CR4","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1200\/JCO.2004.07.173","volume":"22","author":"F Innocenti","year":"2004","unstructured":"Innocenti F, Undevia SD, Iyer L et al (2004) Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22(8):1382\u20131388. \n                    https:\/\/doi.org\/10.1200\/JCO.2004.07.173","journal-title":"J Clin Oncol"},{"issue":"11","key":"1347_CR5","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1111\/j.1349-7006.2006.00321.x","volume":"97","author":"K Araki","year":"2006","unstructured":"Araki K, Fujita K, Ando Y et al (2006) Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci 97(11):1255\u20131259. \n                    https:\/\/doi.org\/10.1111\/j.1349-7006.2006.00321.x","journal-title":"Cancer Sci"},{"issue":"7","key":"1347_CR6","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/FPC.0b013e328014341f","volume":"17","author":"H Minami","year":"2007","unstructured":"Minami H, Sai K, Saeki M et al (2007) Irinotecan pharmacokinetics\/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genom 17(7):497\u2013504. \n                    https:\/\/doi.org\/10.1097\/FPC.0b013e328014341f","journal-title":"Pharmacogenet Genom"},{"issue":"1","key":"1347_CR7","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1200\/JCO.1993.11.1.196","volume":"11","author":"D Gandia","year":"1993","unstructured":"Gandia D, Abigerges D, Armand JP et al (1993) CPT-11-induced cholinergic effects in cancer patients. J Clin Oncol 11(1):196\u2013197. \n                    https:\/\/doi.org\/10.1200\/JCO.1993.11.1.196","journal-title":"J Clin Oncol"},{"issue":"11","key":"1347_CR8","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/jjco\/28.11.709","volume":"28","author":"T Miya","year":"1998","unstructured":"Miya T, Fujikawa R, Fukushima J et al (1998) Bradycardia induced by irinotecan: a case report. Jpn J Clin Oncol 28(11):709\u2013711","journal-title":"Jpn J Clin Oncol"},{"issue":"4_suppl","key":"1347_CR9","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1200\/JCO.2018.36.4_suppl.859","volume":"36","author":"H Fujii","year":"2018","unstructured":"Fujii H, Hirata T, Mura T et al (2018) Relation between irinotecan-induced cholinergic syndrome and prognosis of colorectal cancer patients. J Clin Oncol 36(4_suppl):859. \n                    https:\/\/doi.org\/10.1200\/JCO.2018.36.4_suppl.859","journal-title":"J Clin Oncol"},{"issue":"6","key":"1347_CR10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s12032-018-1142-3","volume":"35","author":"Y Kanbayashi","year":"2018","unstructured":"Kanbayashi Y, Ishikawa T, Kanazawa M et al (2018) Predictive factors for the development of irinotecan-related cholinergic syndrome using ordered logistic regression analysis. Med Oncol 35(6):82. \n                    https:\/\/doi.org\/10.1007\/s12032-018-1142-3","journal-title":"Med Oncol"},{"issue":"6","key":"1347_CR11","first-page":"2236","volume":"6","author":"HC Pitot","year":"2000","unstructured":"Pitot HC, Goldberg RM, Reid JM et al (2000) Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. Clin Cancer Res 6(6):2236\u20132244","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1347_CR12","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1006\/taap.2001.9293","volume":"177","author":"C Blandizzi","year":"2001","unstructured":"Blandizzi C, De Paolis B, Colucci R et al (2001) Acetylcholinesterase blockade does not account for the adverse cardiovascular effects of the antitumor drug irinotecan: a preclinical study. Toxicol Appl Pharmacol 177(2):149\u2013156. \n                    https:\/\/doi.org\/10.1006\/taap.2001.9293","journal-title":"Toxicol Appl Pharmacol"},{"issue":"6","key":"1347_CR13","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s00280-003-0659-z","volume":"52","author":"N Tsavaris","year":"2003","unstructured":"Tsavaris N, Ziras N, Kosmas C et al (2003) Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study. Cancer Chemother Pharmacol 52(6):514\u2013519. \n                    https:\/\/doi.org\/10.1007\/s00280-003-0659-z","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"1347_CR14","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1038\/sj.bjc.6602172","volume":"91","author":"NE Schoemaker","year":"2004","unstructured":"Schoemaker NE, Kuppens IE, Moiseyenko V et al (2004) A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer. Br J Cancer 91(8):1434\u20131441. \n                    https:\/\/doi.org\/10.1038\/sj.bjc.6602172","journal-title":"Br J Cancer"},{"issue":"2","key":"1347_CR15","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","volume":"22","author":"C Tournigand","year":"2004","unstructured":"Tournigand C, Andr\u00e9 T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22(2):229\u2013237. \n                    https:\/\/doi.org\/10.1200\/JCO.2004.05.113","journal-title":"J Clin Oncol"},{"issue":"2","key":"1347_CR16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1056\/NEJMoa003034","volume":"346","author":"K Noda","year":"2002","unstructured":"Noda K, Nishiwaki Y, Kawahara M et al (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346(2):85\u201391. \n                    https:\/\/doi.org\/10.1056\/NEJMoa003034","journal-title":"N Engl J Med"},{"issue":"67","key":"1347_CR17","doi-asserted-by":"publisher","first-page":"111346","DOI":"10.18632\/oncotarget.22795","volume":"8","author":"K Yoshida","year":"2017","unstructured":"Yoshida K, Iwashita T, Uemura S et al (2017) A multicenter prospective phase II study of first-line modified FOLFIRINOX for unresectable advanced pancreatic cancer. Oncotarget 8(67):111346\u2013111355. \n                    https:\/\/doi.org\/10.18632\/oncotarget.22795","journal-title":"Oncotarget"},{"issue":"4","key":"1347_CR18","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1159\/000337225","volume":"82","author":"Y Sunakawa","year":"2012","unstructured":"Sunakawa Y, Fujita K, Ichikawa W et al (2012) A phase I study of infusional 5-fluorouracil, leucovorin, oxaliplatin and irinotecan in Japanese patients with advanced colorectal cancer who harbor UGT1A1*1\/*1,*1\/*6 or *1\/*28. Oncology 82(4):242\u2013248. \n                    https:\/\/doi.org\/10.1159\/000337225","journal-title":"Oncology"},{"issue":"4","key":"1347_CR19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJMoa033025","volume":"351","author":"D Cunningham","year":"2004","unstructured":"Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4):337\u2013345. \n                    https:\/\/doi.org\/10.1056\/NEJMoa033025","journal-title":"N Engl J Med"},{"issue":"31","key":"1347_CR20","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","volume":"28","author":"M Peeters","year":"2010","unstructured":"Peeters M, Price TJ, Cervantes A et al (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28(31):4706\u20134713. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.27.6055","journal-title":"J Clin Oncol"},{"issue":"8","key":"1347_CR21","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1093\/annonc\/mdw206","volume":"27","author":"K Yamazaki","year":"2016","unstructured":"Yamazaki K, Nagase M, Tamagawa H et al (2016) Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Ann Oncol 27(8):1539\u20131546. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdw206","journal-title":"Ann Oncol"},{"issue":"28","key":"1347_CR22","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","volume":"30","author":"E Cutsem Van","year":"2012","unstructured":"Van Cutsem E, Tabernero J, Lakomy R et al (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30(28):3499\u20133506. \n                    https:\/\/doi.org\/10.1200\/JCO.2012.42.8201","journal-title":"J Clin Oncol"},{"issue":"5","key":"1347_CR23","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","volume":"16","author":"J Tabernero","year":"2015","unstructured":"Tabernero J, Yoshino T, Cohn AL et al (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16(5):499\u2013508. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(15)70127-0","journal-title":"Lancet Oncol"},{"issue":"2","key":"1347_CR24","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.ygyno.2005.10.013","volume":"100","author":"K Matsumoto","year":"2006","unstructured":"Matsumoto K, Katsumata N, Yamanaka Y et al (2006) The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer. Gynecol Oncol 100(2):412\u2013416. \n                    https:\/\/doi.org\/10.1016\/j.ygyno.2005.10.013","journal-title":"Gynecol Oncol"},{"issue":"35","key":"1347_CR25","doi-asserted-by":"publisher","first-page":"4438","DOI":"10.1200\/JCO.2012.48.5805","volume":"31","author":"S Hironaka","year":"2013","unstructured":"Hironaka S, Ueda S, Yasui H et al (2013) Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 31(35):4438\u20134444. \n                    https:\/\/doi.org\/10.1200\/JCO.2012.48.5805","journal-title":"J Clin Oncol"},{"issue":"5","key":"1347_CR26","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1200\/JCO.1993.11.5.909","volume":"11","author":"Y Shimada","year":"1993","unstructured":"Shimada Y, Yoshino M, Wakui A et al (1993) Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 11(5):909\u2013913. \n                    https:\/\/doi.org\/10.1200\/JCO.1993.11.5.909","journal-title":"J Clin Oncol"},{"issue":"9","key":"1347_CR27","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1470-2045(10)70181-9","volume":"11","author":"K Muro","year":"2010","unstructured":"Muro K, Boku N, Shimada Y et al (2010) Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2\/3 non-inferiority study (FIRIS study). Lancet Oncol 11(9):853\u2013860. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(10)70181-9","journal-title":"Lancet Oncol"},{"issue":"2","key":"1347_CR28","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/jnci\/90.2.160","volume":"90","author":"J Valencak","year":"1998","unstructured":"Valencak J, Raderer M, Kornek GV et al (1998) Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin. J Natl Cancer Inst 90(2):160","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1347_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.12788\/jcso.0099","volume":"13","author":"C Cheng","year":"2015","unstructured":"Cheng C, Lau JE, Earl MA (2015) Use of atropine-diphenoxylate compared with hyoscyamine to decrease rates of irinotecan-related cholinergic syndrome. J Commun Support Oncol 13(1):3\u20137. \n                    https:\/\/doi.org\/10.12788\/jcso.0099","journal-title":"J Commun Support Oncol"},{"issue":"6","key":"1347_CR30","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/cam4.433","volume":"4","author":"ReW Marsh","year":"2015","unstructured":"Marsh ReW, Talamonti MS, Katz MH et al (2015) Pancreatic cancer and FOLFIRINOX: a new era and new questions. Cancer Med 4(6):853\u2013863. \n                    https:\/\/doi.org\/10.1002\/cam4.433","journal-title":"Cancer Med"},{"issue":"8","key":"1347_CR31","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1177\/1756283X17713879","volume":"10","author":"A Lambert","year":"2017","unstructured":"Lambert A, Gavoille C, Conroy T (2017) Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions. Therap Adv Gastroenterol 10(8):631\u2013645. \n                    https:\/\/doi.org\/10.1177\/1756283X17713879","journal-title":"Therap Adv Gastroenterol"},{"issue":"1","key":"1347_CR32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.2133\/dmpk.DMPK-13-RV-103","volume":"29","author":"K Fujita","year":"2014","unstructured":"Fujita K, Sasaki Y (2014) Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the \u2018real world\u2019. Drug Metab Pharmacokinet 29(1):20\u201328","journal-title":"Drug Metab Pharmacokinet"},{"issue":"4","key":"1347_CR33","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1067\/mcp.2002.121909","volume":"71","author":"C Blandizzi","year":"2002","unstructured":"Blandizzi C, Danesi R, De Paolis B et al (2002) Cholinergic toxic syndrome by the anticancer drug irinotecan: acetylcholinesterase does not play a major role. Clin Pharmacol Ther 71(4):263\u2013271. \n                    https:\/\/doi.org\/10.1067\/mcp.2002.121909","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"1347_CR34","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1093\/annonc\/mdn645","volume":"19","author":"Y Akiyama","year":"2008","unstructured":"Akiyama Y, Fujita K, Nagashima F et al (2008) Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapy. Ann Oncol 19(12):2089\u20132090. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdn645","journal-title":"Ann Oncol"},{"issue":"14","key":"1347_CR35","doi-asserted-by":"publisher","first-page":"8170","DOI":"10.1073\/pnas.95.14.8170","volume":"95","author":"E Beutler","year":"1998","unstructured":"Beutler E, Gelbart T, Demina A (1998) Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 95(14):8170\u20138174","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"1347_CR36","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/sj.clpt.6100513","volume":"84","author":"FA Jong de","year":"2008","unstructured":"de Jong FA, van der Bol JM, Mathijssen RH et al (2008) Renal function as a predictor of irinotecan-induced neutropenia. Clin Pharmacol Ther 84(2):254\u2013262. \n                    https:\/\/doi.org\/10.1038\/sj.clpt.6100513","journal-title":"Clin Pharmacol Ther"},{"issue":"19","key":"1347_CR37","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1200\/JCO.2006.09.6115","volume":"25","author":"JM Bol van der","year":"2007","unstructured":"van der Bol JM, Mathijssen RH, Loos WJ et al (2007) Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J Clin Oncol 25(19):2719\u20132726. \n                    https:\/\/doi.org\/10.1200\/JCO.2006.09.6115","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-018-1347-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-018-1347-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-018-1347-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T19:17:20Z","timestamp":1569093440000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-018-1347-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,22]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["1347"],"URL":"https:\/\/doi.org\/10.1007\/s10147-018-1347-7","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,22]]},"assertion":[{"value":"31 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors have no conflict of interest to declare in association with this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}